ARCT

Over the past six months, Arcturus Therapeutics' stock has experienced several notable events. In December 2025, ARCT stock plunged 59% in three months. In November 2025, Citigroup and Piper Sandler maintained their recommendations for ARCT, and the company reported Q3 2025 results with revenue declines and a net loss. In March 2026, Arcturus reported its Q4 and fiscal year 2025 financial results, with decreased research and development expenses and B. Riley Securities initiated coverage with a Buy recommendation. In May 2026, the company announced Q1 2026 financial results, reporting a revenue drop and a widened net loss, but reiterated a cash runway extending beyond Q2 2028. The European Commission granted marketing authorization for KOSTAIVE (Arct-154).